Trump honeymoon over as global equities markets plunge in unison

Published 31-JAN-2017 14:47 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

President Trump’s honeymoon period could be the shortest in US political history if the unravelling of last week’s stock market gains are an indication.

There was more to the fall than just the Dow being off more than 200 points at one stage, it was the fact that the falls could be traced back to sectors and stocks which stand to be potentially hurt by policy changes by the new administration.

For example, Mexico is one of the largest importers of US grains and China is the largest importer of US soybeans. Both these soft commodities have fallen substantially in recent days and this trend accelerated overnight.

US continues to build walls while sun sets on international relationships

Rather than embracing the unknown US investors now appear to be examining the potential cause-and-effect relationships that can be drawn between Trump’s policies and certain industries and sectors.

While the decline in the Dow was also impacted by the falling oil prices and negative commentary regarding rig counts, the fact that the volatility index (VIX) spiked 17% suggested there was more to the fall than concerns regarding one commodity.

After falling from the previous day’s close of 20,093 points to an intraday low of 19,870 points, the Dow pushed up towards 19,920 points as markets drew to a close.

This represented a fall of 0.8%, and the NASDAQ was also down more than 1% with sharp declines experienced by Intel, Microsoft, Cisco Systems and IBM. Silicon Valley is home to some of the smartest minds that are headhunted by the biggest global tech companies from overseas destinations, a trend that could be railroaded by the Trump administration.

Consequently, this development which also affected stocks such as Google and Facebook indicates that investors are starting to join the dots and the days of broad-based euphoria that pushed both the Dow and the NASDAQ up to record levels may be over.

Markets in Europe were also negatively impacted by concerns over Trump’s immigration changes with the tourism and travel sector one of the hardest hit.

The FTSE 100, Dax and Paris CAC 40 were all down circa 1%.

On the commodities front oil was down by approximately 1%, while gold rallied circa 0.6%, briefly touching US$1200 per ounce in morning trading before pulling back to close just shy of that mark.

Base metals were mixed with copper down slightly, while nickel, zinc and lead made good gains. Having spiked 2.7 US cents per pound overnight, lead is just shy of the US$1.10 per pound mark, a level it hasn’t traded at for approximately four years.

The Australian dollar was relatively unmoved at US$0.755.

It should be noted that broker projections and price targets are only estimates and may not be met. Also, historical data in terms of earnings performance and/or share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free